Prosight Management, LP Adma Biologics, Inc. Transaction History

Prosight Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$1.13 - $1.65 $130,062 - $189,915	-115,100 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$1.51 - $2.07 $577,940 - $792,275	-382,742 Reduced 76.88%	115,100 $184,000
Q1 2021 May 14, 2021	SELL	$1.67 - $2.95 $643,571 - $1.14 Million	-385,372 Reduced 43.63%	497,842 $876,000
Q4 2020 Feb 12, 2021	BUY	$1.8 - $2.56 $626,202 - $890,598	347,890 Added 64.99%	883,214 $1.72 Million
Q3 2020 Nov 13, 2020	SELL	$2.04 - $3.74 $1.56 Million - $2.86 Million	-763,976 Reduced 58.8%	535,324 $1.28 Million
Q2 2020 Aug 14, 2020	BUY	$2.42 - $3.29 $136,972 - $186,214	56,600 Added 4.55%	1,299,300 $3.81 Million
Q1 2020 May 15, 2020	BUY	$1.5 - $4.59 $1.86 Million - $5.7 Million	1,242,700 New	1,242,700 $3.58 Million
Q4 2019 Feb 14, 2020	SELL	$3.89 - $5.15 $2.13 Million - $2.82 Million	-548,409 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.19 - $5.39 $1.16 Million - $1.95 Million	362,688 Added 195.29%	548,409 $2.44 Million
Q2 2019 Aug 14, 2019	BUY	$3.52 - $5.24 $653,737 - $973,178	185,721 New	185,721 $719,000

319

184M

917K

91.6K

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.42B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.